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Microencapsulation for Clinical 
Applications and Transplantation 
by Using Different Alginates
Beyza Goncu and Emrah Yucesan
Abstract
Microencapsulation has been the most frequently used technique for several dif-
ferent disciplines such as cell-based therapies and/or transplantation. Technology is 
based on the idea of combining and coating a material or isolating from an external 
source. Microencapsulation may be performed with different materials and, among 
natural biocompatible materials, alginate-based microencapsulation technique is the 
most appropriate material for microencapsulation. The structural components of 
alginate materials are the derivatives of alginic acid, which is found in brown algae 
as an intercellular gel matrix. This alginate is preferred for clinical applications due 
to its safety in human studies. Therefore, the choice and the combined system need 
to be carefully optimized to achieve biocompatible application through cell micro-
encapsulation especially for long term. Specifications of alginate such as primary 
source, isolation process, viscosity, and purity contribute to improve its biocompat-
ibility. Clinically, cell microencapsulation is the major contribution to the field of 
transplantation by its technique and additionally provides local immune isolation. 
This chapter discusses the potential benefits of clinically suitable alginates and their 
applications. This promising technology may highlight its considerable potential for 
patients that require transplantation and/or replacement therapy in the future.
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1. Introduction
Cell encapsulation is a process that involves immune protection of the living cell 
by using different polymers. The polymers can be distinguished into two main groups: 
natural origin (i.e., polysaccharides, polynucleotides, polypeptides) [1] and synthetic 
polymers (i.e., polyethylene glycol, polyvinyl alcohol, polyurethane, etc.). Several 
attempts have been made by scientists to use natural, synthetic, and semi-synthetic 
polymers in the field of encapsulation. The first approach was made in 1933 by Bisceglie 
et al. and used enveloped membrane to demonstrate tumor cell survival in the abdomi-
nal cavity of guinea pigs [2]. In his report, the cells survived for 12 days by diffusion of 
the nutrients. However, at that time immunoisolation technology was not known or 
understood [3]. Later, in 1943 Algire et al. reported a transparent chamber for athera-
peutic approach in vivo [4]. Since this report, therapeutic demands enhanced this encap-
sulation technology in a way that combines the polymer source (produced synthetically 
or isolated from natural sources) and their functionality by using its characterization.
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Several advantages and disadvantages have been reported about synthetic 
polymers [5]. Mechanical specifications can be more easily engineered or modi-
fied with the desired characteristics and particularly can be produced with larger 
amounts [6–8]. The main deficit of synthetic polymers is that they require toxic 
substances during the capsulation process; therefore, cell viability is a true obstacle 
after encapsulation [8, 9]. In this regard, synthetic polymers are frequently used in 
combination with different devices such as macrocapsules. Before accommodation 
of the encapsules, first, synthetic polymers are manufactured in the absence of 
living tissue/cells, and second, tissue/cells are combined with the device to preserve 
direct contact of the toxic solvents [1]. The most common synthetic polymers are 
poly(ethylene glycol) [10], polyvinyl alcohol [11], polyurethane [12], poly(ether 
sulfone) [13], polypropylene [14], sodium polystyrene sulfate [15], polyacrylate 
[16], polyphosphazene [17], AN69 [18], and lastly polytetrafluoroethylene [19].
Natural polymers have been proposed for immunoisolation based on two 
distinct features. First, there is no interference with the functionality of cells/tis-
sues and second, the stability of the structure they provide during encapsulation 
[1, 20]. Conventionally, the most frequently used polymers from natural sources 
are cellulose [21], chitosan [22], collagen [23], agarose [24], and alginate [25]. The 
experimental success mainly depends on the application and mimicry potential 
of the natural polymers. Among these, in this chapter, we mainly focused on the 
alginate-based encapsulation and its clinical application.
2. Alginates
The most versatile biomaterials among natural polymers are alginates, which 
are used in a wide range of applications including diffusion systems, drug deliv-
ery, as a wound dressing, and for encapsulation when the transplantation has to 
be a substitute [25–27]. Alginates are hydrophilic compounds that are naturally 
found in the cell wall, extracellular matrix of brown algae and some species of 
bacteria, for example, Pseudomonas aeruginosa and Azotobacter vinelandii [26, 27]. 
The most common algae source is brown seaweed. During alginate extraction, 
alginic acid is generally obtained and converted to a form of salt [26]. Several 
forms of alginates are currently approved by the Food and Drug Administration 
(FDA) for use, particularly in the replacement of missing/nonfunctioning endo-
crine-related diseases [28].
2.1 Gelling and ionic cross-linking of alginates
Alginates are linear copolymers that include two hexuronic acid residues that 
become dimeric blocks, which are composed of 𝛽-D-mannuronic (M) and 𝛼-L-
guluronic (G) acids for building the entire molecule [29]. These blocks are known 
as the building blocks of alginates. Mainly, the ratio of G and M blocks depends 
on the source of the algae type [9]. The important feature of these building blocks 
is the sensitivity to binding of multivalent cations. This is the starting point of 
this water-soluble polysaccharide, which allows alginate to form as hydrogels. 
This characteristic of the hydrogel equilibrates between the environment and the 
relatively physiologic internal environment [29]. The divalent cations and hydrogel 
feature depends on the divalent ion’s affinity to alginate. Several studies reported 
high-rate ion affinity results in a stronger gel structure. In order to decrease the 
ion binding strength, divalent cations should be chosen from the following order: 
Pb2+>Cu2+>Cd2+>Ba2+>Sr2+>Ca2+>Co2+>Ni2+>Zn2+>Mn2+ [1, 29, 30] (Figure 1). 
Controlling cation addition to maintain a porous alginate structure is a critical step.
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Successful formation of alginate spheres for delivery purposes requires 
suitable and selective methods. In 2006, Darrabie et al. identified gelling-cation 
stability by determining swelling, which contributes to colloid osmotic pres-
sure. They suggested that Ca2+ is more hygroscopic and less prominent swelling 
occurs when compared with Ba2+ [32]. Protecting the conformational polymer 
blocks during preparation of the alginate gels for microencapsulation has been 
reported using different methods including conjugation of long alkyl chains [33] 
or dodecylamine [34], temperature (up to 60°C ± 1°C) [35, 36], emulsification 
by cationic agent [37], and ionotropic gelation of alginate layers [38], etc. Slow 
gelation utilizes the alginate solution in a more uniform structure in a gradual 
manner [35].
In the latter case, Lee et al. reported a degree of cross-linking of the alginate 
can influence a low dose of drug entrapment and unsuitable pore sizes for trans-
plantation. In addition, the efficiency of the microcapsule size or content was 
found irrelevant, although the preparation step of the water-soluble alginate itself 
appears to be responsible for the arrangement of the polymer blocks [37]. Cross-
linking capacity of the alginates can be modifiable and flexible (Figure 2). There 
are more than 200 types of biocompatible alginates manufactured so far [25, 26]. 
Moreover, due to the different cross-linking degree of various alginate types, switch 
in homogenous distribution of the graft/drug during the encapsulation process may 
occur [36].
Both features of alginates promote several advantages over other polymers such 
as the stability of the building blocks (-G and/or/both -M repetitively); elasticity 
of the alginate hydrogel; surface roughness, which is related to elasticity as well, 
approximately 1% of the alginate can entrap a hundred times more water than its 
weight; and lastly permitting the ability of oxygen and nutrient permeation inside 
the spheres.
Figure 1. 
Representative image for the formation of egg-box ionic cross-links between guluronic acid-rich monomer units 
(box) and the divalent cations (eggs). Reprinted from Baumberger and Ronsin (2009) [31], an open access 
article distributed under the terms of the creative commons by attribution 4.0 (CC-BY 4.0).
Figure 2. 
Representative image of alginate gelation process by continued calcium cations. Reprinted from Dumitru 
et al. [39], an open access article distributed under the terms of the creative commons by attribution 4.0 
(CC-BY 4.0).
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2.2 Biotolerability over biocompatibility
Source-dependent impurities may have detrimental effects. Safe and effective 
delivery of the therapeutic graft/drug with the alginate carrier is frequently men-
tioned as biocompatible. This naturally derived product provides immunoprotection 
and most of the studies reported purity of its building block structure preventing a 
host response when transplanted. Therefore, this makes alginate the most common 
material for microencapsulation. Higher water-carrying capability of alginates has 
been shown to directly maintain diffusion and this shows immune-safe characteris-
tics [3]. A decade ago, Kendall et al. focused on the various components of alginate 
blocks and compared their purity and sphere sizes depending on the cationic agent. 
They reported that higher purification of alginate prevents imperfections and size/
shape properties would affect immunogenicity [40]. Several other reports also dem-
onstrated that -G and -M blocks of the alginate gel need a balance whereas the distri-
bution of these proportions indicates the biocompatibility of the purified alginate is 
influenced by its viscosity [41–43]. One of the most obvious results from the studies 
that explains the difference between the building block’s balance in alginate gels is 
higher -M blocks mainly stimulate and induce an immune response [41, 44–46].
There are many immunogenic substances such as endotoxins, proteins, and 
polyphenols in natural polymers including alginates. Those molecules may diffuse 
the outer surface from the capsules and then induce an unwanted immune response 
against the capsules [3]. There are highly conserved molecular motifs that are 
present in nature and pathogens known as pathogen-associated molecular patterns 
(PAMPs). PAMPs provoke pattern recognition receptors (PRRs) to enhance inflam-
matory response [47]. The presence of PAMPs in natural products and alginate as 
well is not a direct threat; however, complement activation has been reported for 
encapsulated islets [48]. Therefore, complement activation has a more destructive 
effect than the inflammatory response; it may activate and produce large quantities 
of cytokines to induce a stronger response.
Immunoprotective properties still require the exact characterization and prep-
aration of the material to be used as a delivery agent. Despite giving most of the 
efforts to optimize the encapsulation process, the applicability of this technology 
has still resulted in an insufficient investigation of graft/drug delivery. In 2014, 
Rokstad et al. described the duration and the type of host responses and divided 
the whole process into three categories: acute inflammation, chronic inflamma-
tion, and the long-lasting granulation tissue phase [48]. Based on the publications 
from islet transplantation studies, it was reported that the granulation phase 
mainly refers to the “vascularized fibrous tissue containing a moderate epithelial 
histiocytic response” [49–52]. Solely, it is important to observe these responses 
and that leads to the question: Why do alginate microencapsules contribute to 
these chain of events even when their purity, stability, and biocompatibility 
are comparable to most other polymers? Immunocompatibility of the alginate 
microencapsules should not be determined only by the features of alginate and 
its preparation process, but should also be evaluated for its protein absorption 
capability as well.
A profound impact might be introduced with the biotolerability term. 
Biotolerability is a term for a strategy of making biocompatible encapsulations to 
induce none/minimal host response. A seemingly minimal cellular overgrowth 
for graft provides the free diffusion of nutrients, oxygen, and some therapeutic 
proteins, and controlled drug release from the microcapsules. We should emphasize 
that the alginate microspheres are not meant to prevent an immune response yet 
to protect the carrier against an immune response. Therefore, the biocompatibility 
term not clear enough to explain the biotolerability of the carrier system.
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2.3 Vascularization
The vascularization process of the microencapsules is another requirement to 
increase the survival of the transplanted graft. Sufficient vascularization may be 
achieved by improving the physical features of the spheres such as the size of the 
spheres or micropores and the amount/density of the graft/cells. The main argu-
ment against vascularization is hypoxia and oxidative stress whereby it develops 
inside the microspheres [53]. Insufficient oxygenation and nutrition occur particu-
larly in the absence of ideal vascularization. A prerequisite is that the functional 
performance of the microencapsules often depends on the surface-to-volume 
ratio. This implies that free diffusion of nutrients and oxygen is necessary and this 
directly interferes with vascularization.
The majority of researchers developed different strategies to allow a fast 
exchange of nutrition and demonstrated several boundaries to ensure a low or no 
inflammatory response while supplying oxygen-nutrients inside [29, 53]. Currently, 
the accepted limitations of the islet transplantation are defined with three main 
strategies: first, the cell-to-volume ratio should not exceed 10% even if a large 
number of cells are required to reach curative treatment. Second, microencapsules 
should be kept <1 mm, once they reach the spheres they do not maintain their 
biphasic effect (releasing insulin after a glucose challenge) and also an immune 
response may be triggered. Third, direct vascular access of the microencapsules 
to the optimal transplantation site, for instance, glucose must pass and be observed 
in the transplantation site and then islets release insulin to diffuse through circula-
tion. The whole process requires time and larger amounts to reach an effective dose 
to lower glucose [1, 53, 54].
3. Clinical applications
A broad range of clinical applications of the microencapsulation process have 
shown promising results despite encountering some biotolerability issues. Multiple 
disciplines have been using this alginate encapsulation technology including 
chemistry, protein science, and cell therapy (mostly transplantation and immunol-
ogy field). The most studied and reported diseases include Type 1 diabetic patients 
(T1DM) [55], permanent hypoparathyroidism patients [56], scaffold systems for 
tissue engineering [57], bone regeneration [58, 59], leukemia (an in vivo study that 
uses alginate to encapsulate specialized hybridoma cells) [60], and even neurode-
generative diseases [61]. Some of the clinical studies about cell therapy are compiled 
in Table 1.
Based on the current experience with alginate, most of the studies have already 
performed transplantation of beta-cells (islets). The first and well-known clinical 
trial with islet transplantation was performed in 1994 by Soon-Shiong et al. They 
reported 9 months of survival of the microencapsules, which were prepared with 
high guluronic acid containing alginate [49]. Another case reported how islet trans-
plantation was prepared with alginate- poly-l-ornithine and that the patient’s need 
for insulin decreased after transplantation [62]. Following two case reports, Tuch 
et al. used barium alginate to encapsulate islets and transplanted these into four 
recipients. In their report, grafts showed various survival rates and did not restore 
insulin requirements [51]. Considering the last case reports, several companies took 
the stage and initiated clinical trials to overcome T1DM by using macro- and micro-
encapsulation with alginate and other polymers. In 2014, Scharp and Marchetti 
evaluated the outcomes of islet encapsulation from companies with larger clinical 
studies, respectively. The increased interest in islet transplantation reached its most 
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popular level between 2010 and 2012 [54]. For the last 2 years, researchers provided 
detailed in vivo experiments and defined an alginate encapsulation strategy in a 
more enhanced way [52, 60, 70, 71] . The vast majority of attempts have been made 
to treat T1DM and the critical requirements remain to be elucidated in the future.
Another endocrine replacement therapy performed for hypoparathyroidism 
by encapsulated parathyroid tissue/cell transplantation (PTX) was described 
only in seven case reports for 12 recipients [43, 56, 67–69, 72, 73] between 1997 
and 2019. Six of these case studies used alginate for encapsulation. In 1997, Hasse 
et al. performed the first microencapsulated PTX for two recipients and reported 
3 months of graft survival [72]. The second one, performed by Zimmerman et al. 
in 2001 for one recipient showed no trace of parathyroid tissue particles nor 
microcapsules, after 3 months, from histological samples from the implantation 
site of the recipient [43]. The third transplantation case reported up to 1 year graft 
survival by Tibell et al. and they had macroencapsulated the parathyroid tissue 
particles and transplanted into four recipients [67]. Another case by Ulrich et al. 
reported two PTX recipients had elevations in PTH levels and reduced the supple-
mentation requirement into half dose [68]. In 2009, Cabane et al. microencapsu-
lated the enzymatically isolated parathyroid cells in one recipient and reported 
the longest follow-up data with 20 months of graft survival [69]. The last and 
seventh case performed by Yucesan et al. in 2019 microencapsulated parathyroid 
cell transplantation for one recipient reported and the results followed for a year 
with success [56]. Despite these achievements, the necessity of immunoisolation 
for parathyroid allotransplantation requires more case studies with long-term 
follow-up data.
Alginate type Graft survival Graft Year Reference
Alginate high in 
guluronic acid
9 months Beta-cells (Islets) 1994 [49]
Ultrapure alginate (68% 
glucuronic acid)
3 months Beta-cells (Islets) 2013 [50]
Barium alginate Various duration for 
four recipients
Beta-cells (Islets) 2009 [51]
poly-l-ornithine-sodium 
alginate
<1 year Beta-cells (Islets) 2006 [62]
Ultra-purified sodium 
alginate
3 years Beta-cells (Islets) 2011 [63]
Alginate-Poly-L-
Ornithine
<8 months Beta-cells (Islets) 2010 [64]
Collagen/Alginate n/a Beta-cells (Islets) 2010 [65]
Sodium alginate 3 months Parathyroid cells 1997 [66]
Amitogenic alginate <3 months Parathyroid cells 2001 [43]
n/a 1 year Parathyroid tissue 
particles
2001 [67]
n/a n/a Parathyroid cells 2004 [68]
Sodium alginate <20 months Parathyroid cells 2009 [69]
Ultrapure-low viscosity 
high guluronic acid-rich 
alginate
>1 year Parathyroid cells 2019 [56]
Table 1. 
Some of the examples of alginate derivates used in microencapsulation studies.
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A different therapy for using microencapsulation is cell therapy for neurode-
generative diseases. The development of a delivery strategy is limited due to the 
blood–brain barrier; however, principle studies in animal models may offer new 
approaches including gene delivery, cell-based delivery, and also biomaterial drug 
delivery [61]. In the past year, several in vivo studies have been reported for neuro-
degenerative diseases [71, 74–76]. Galli et al. used alginate-poly-L-lysine-alginate 
(APA) microcapsules and cross-linked the spheres with both Ca2+ and Ba2+. They 
have used this system as a transporter to carry a specialized cell clone for codon 
optimization of the cerebral dopamine neurotrophic factor gene. According to their 
recent data, this system has the potential to deliver polymer-encapsulated-drug 
conjugates for the treatment of Parkinson’s and Alzheimer’s diseases [76].
4. Conclusion
Immunoisolating construct tuning may be achieved by defining the mechanical 
properties, molecular weight, cross-linking density of the polymer, and the con-
centration balance between the therapeutic graft/drug and the biomaterial. These 
proportions still require optimal decisions even with the known performances of 
encapsulated cells.
Significant efforts have been made so far by ongoing studies from research labo-
ratories and biotechnology companies, which continue to encounter microencapsu-
lation strategies at every step. The future perspective is strong enough to overcome 
the current limitations. Nevertheless, alginate is the best natural product to be used 
by many different disciplines at the same time.
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